BW-20805 Sustains Prekallikrein Suppression in Phase 1 HAE Trial Mean maximum reductions of prekallikrein from baseline were 75% at 50 mg, 87% at 150 mg, 94% at 300 mg, and 95% at 600 mg.

#ACAAI25: BW-20805 safely and significantly reduced levels of #PlasmaPrekallikrein for up to 24 weeks after a single dose in healthy volunteers, supporting its potential as a long-acting preventive therapy for #HereditaryAngioedema (HAE)

Read here: https://bit.ly/3Jt4YFs

#RareDisease #BW20805 #HAE